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PATIENT PERCEPTION OF NEGATIVE NON-INVASIVE PRENATAL TESTING
RESULTS
Ann Theresa Wittman, BS
Advisory Professor: Claire Singletary, MS, CGC
Abstract
	
  
Non-invasive prenatal testing (NIPT) uses cell-free fetal DNA to assess for fetal aneuploidy
during pregnancy. NIPT has higher detection rates and positive predictive values than
previous methods; however, NIPT is not diagnostic. Studies suggest patients may
underestimate the limitations of prenatal screening. Therefore, we conducted a prospective
cross-sectional study of ninety-four women from genetic counseling clinics in Houston,
Texas to assess patient understanding of the residual risk for aneuploidy after receiving a
negative NIPT. The majority of participants (66%) understood the residual risk for Down
syndrome following negative NIPT; however, 34% of participants indicated that negative
NIPT completely eliminated the risk. Individuals with at least four years of college education
were more likely to understand that NIPT does not eliminate the chance of trisomy 13/18
(p=0.012) and sex chromosome abnormality (p=0.039), and were more likely to understand
which conditions NIPT tests for (p=0.021), compared to women with less formal education.
These data demonstrate that despite the recent implementation of NIPT into obstetric
practice, the majority of women are aware of its limitations after genetic counseling.
However, clinicians may need to consider alternative ways to communicate the limitations of
NIPT to those women with less formal education to ensure understanding.
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Introduction
Chromosomal aneuploidy is estimated to occur in 1/160 live births, the vast majority
consisting of trisomy 21, trisomy 18, trisomy 13, and sex chromosome conditions (Driscoll et
al., 2009). Before the advent of recent prenatal testing options, women seeking information
about aneuploidy in their pregnancy generally had two options: invasive diagnostic testing
that confers a risk for miscarriage or non-invasive screening, which generally had false
positive rates of 5% or more and positive predictive values between 1 and 10% (Wapner,
2003; BJOG, 2005).
In November 2011, Non-Invasive Prenatal Testing (NIPT), or prenatal cell free fetal
DNA screening, became clinically available for use in high-risk populations. NIPT was
validated in a high-risk population in multiple studies, all of which have shown similar
accuracies for aneuploidy detection (Palomaki, 2011, 2012; Bianchi, 2012; Gil, 2013). The
most recent meta analysis by Gil et al. in 2015 analyzed data from 37 relevant studies and
determined that NIPT detection rates for the most common aneuploidies are approximately
99.2% for trisomy 21, 96.3% for trisomy 18, 91% for trisomy 13 and 90-93% for sex
chromosome aneuploidy. While the detection rates and positive predictive values (PPVs) for
NIPT are increased in comparison to other methods of prenatal screening, NIPT is not a
diagnostic test, and a negative NIPT result does not guarantee a pregnancy is unaffected
(Neufeld-Kaiser et al. 2015). NIPT laboratories' marketing efforts and website content often
focus on the detection rate rather than positive predictive value or residual risk (Mercer et al.
2014). It is unclear whether the general patient population understands this distinction, which
may have implications for downstream uptake of invasive testing and emotional preparation
at birth (Tiller, 2015; Hall, 2000). Therefore, we conducted a prospective cohort study to
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assess patient understanding of the residual risk for trisomy 21, trisomy 18, trisomy 13 and
sex chromosome aneuploidy after receiving a negative NIPT result.
Methods
From August 1, 2015 through January 29, 2016, women who were at least 18 years
old, English or Spanish speaking, and had been consented for NIPT during their genetic
counseling appointment were invited to participate in the study. Participating centers were
staffed by University of Texas Health and Baylor College of Medicine prenatal genetic
counselors in the Houston, Texas area and approved by the Institutional Review Boards: the
University of Texas Health and Memorial Hermann Hospital (HSC-MS-15-0444), Baylor
College of Medicine and affiliated Texas Children’s Hospital (H-37683) and the Harris
Health System (15-09-1193). Those patients willing to take part signed a consent form
agreeing to be contacted after their NIPT results were available (Appendix A), and only those
with a negative result were contacted to participate. The survey consisted of a section
designed to assess patient understanding of the limitations of NIPT, a section to assess worry
level for various conditions, a section regarding subsequent testing, and a section with
demographic information (Appendix B). An online survey tool, Redcap, was used to securely
administer the survey via email and collect the data. Those participants unable to complete
the survey via email were called and given the survey over the telephone. Data from
telephone calls were manually added to the Redcap data set. Data were analyzed using
STATA, (v.14.1, College Station TX). Comparison of data between groups was evaluated
using Chi-square analysis, Fisher exact test, Wilcoxon signed-rank test or Mann Whitney test
where appropriate. Statistical significance was assumed at a Type I error rate of 5%.
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Results
A total of 231 women agreed to participate in the study and be contacted for the
survey. Six women were excluded either due to a positive NIPT result (n=3) or failure to
follow-through with the blood draw (n=3). Two hundred twenty-five women were contacted
after their negative NIPT result and asked to participate in the survey either through email or
phone call. Twenty-nine women (13%) declined to participate after being contacted and 102
women (45%) were never successfully contacted, leaving a total of 94 participants (42%)
from the original 225 consented. Twelve (13%) of the surveys were incomplete, the majority
of which were missing the last several questions of the survey (Figure 1).
Figure 1: Survey Completion Flow Diagram

The majority of participants (59%, n=55) were referred to genetic counseling due to
advanced maternal age and most identified as non-Hispanic White (36%, n=34) or Hispanic
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(29%, n=27). The majority of participants (64%, n=60) reported having at least a four-year
college degree (Table 1).
Table 1: Participant Demographics (n=94)
Participant Demographics
Ethnicity
Non Hispanic White
Hispanic
Afr. American
Asian
Other
No Answer

n
34
27
16
11
5
1

%
36
29
17
12
5
1

Household Income
Less than $25,000
$25,000 to $49,999
$50,000 to $74,999
$75,000 to $99,999
$100,000 to $149,999
$150,000 or more
Do not wish to answer

n
10
15
16
15
20
12
6

%
11
16
17
16
21
13
6

Education
Some high school
High school/GED
Some college
4-year degree
Graduate degree

n
1
11
22
32
28

%
1
12
23
34
30

Marital Status
Married/living with partner
Unmarried
Do not wish to answer

n
84
9
1

%
89
11
1

Age
21-29 years
30-34 years
35-39 years
40-43 years

n
15
15
54
10

%
16
16
57
11

Indication
Advanced Maternal Age
Positive Serum Screen

n
55
11

%
59
12
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Ultrasound Abnormality
Low Risk
Two or More Indications

11
9
8

12
10
9

Patient Perception of Residual Risk Post- Negative NIPT Results
Participants were about their residual risk for Down syndrome, trisomy 13/18, sex
chromosome aneuploidy, and any other genetic syndromes after a negative NIPT result. The
majority of participants indicated their risk was decreased but not eliminated. Sixty-one
percent (n=57) of women indicated their risk to have a baby with Down syndrome was much
lower, 55% (n=52) indicated that their risk was much lower for trisomy 13/18 and 49%
(n=46) said that their risk to have a baby with a sex chromosome aneuploidy was much
lower. A proportion of women also indicated that there was no residual risk after a negative
NIPT. Specifically, 34-39% of participants indicated there was no longer a chance for their
baby to have Down syndrome, trisomy 13/18 or a sex chromosome aneuploidy after
receiving a negative NIPT result. Additionally, participants were asked to indicate their risk
to have a baby with a genetic condition other than Down syndrome, trisomy 13/18 or sex
chromosome aneuploidy after receiving a negative NIPT result. Thirteen percent (n=12)
correctly answered that their risk was not lower than before, 29% (n=27) indicated that there
was no longer any chance for their baby to have any genetic problem, 49% (n=46) answered
that it was much lower than before and 9% (n=8) responded that it was somewhat lower than
before. Women with less than a four-year college education were significantly more likely to
incorrectly respond that there was no longer a risk for their baby to have trisomy 13/18 (p=
0.012) or a sex chromosome abnormality (p= 0.039). Participants with less than a four-year
education also appeared to be more likely to indicate that there was no longer a chance for
their baby to have Down syndrome; however, this did not reach significance (p=0.086).
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Other demographic factors did not show a significant influence on patient perception of
negative NIPT results (Table 2).
Table 2: Patient Perception of Risk Post Negative NIPT (n=94)
Perception of Residual Risk Post Negative NIPT
Down
T13/T18
Sex Chromosome
Syndrome (%)
(%)
Aneuploidy, (%)
Not lower than
0
1
5
before
Somewhat
lower than
5
10
7
before
Much lower
61
55
49
than before
No longer a
34
34
39
chance

Any Other Genetic
Condition, (%)
13
10
49
29

Influence of Demographic Factors on Risk Perception Post Negative NIPT
Down
Sex Chromosome
Any Other Genetic
T13/T18
Syndrome
Aneuploidy
Condition
Ethnicity
p=0.440
p=0.119
p=0.177
p=0.130
Income
p=0.588
p=0.540
p=0.166
p=0.752
Education
p=0.086
p=0.012
p=0.039
p=0.159
Age
p=0.649
p=0.550
p=0.486
p=0.885
Indication
p=0.238
p=0.082
p=0.324
p=0.700

Most Important and Least Important Reasons for Pursuing NIPT
Participants were asked to share the most important and least important reasons for
pursuing NIPT on a scale of one to six, with one being the most important and six being the
least important. There was no significant difference between demographics and how
participants ranked their reasons for pursuing NIPT (ethnicity p = 0.586, income p = 0.747,
education p = 0.212, age p =0.373, indication p = 0.123), (Table 3).
Table 3: Most and Least Important Reasons For Pursuing NIPT (presented as
percentages, n=85)
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Patient Perception of Conditions Tested by NIPT
Participants were asked to indicate whether NIPT could test for the following:
intellectual disability, autism, diabetes, spina bifida, cleft lip, gender and structure of the
heart. The vast majority of participants (92%, n=86) were able to correctly identify that NIPT
can test for gender. When looking at the remaining six items from this question, a participant
had to indicate that NIPT did not test for the item in order to be scored as correct. Cleft lip,
structure of heart and spina bifida were considered structural abnormalities, while intellectual
disability, autism and diabetes were considered non-structural. Those with less formal
education were significantly less likely to recognize what NIPT could not test for and had
lower scores overall (p= 0.021). Fourteen percent (5/36) of women with less formal
education correctly answered all of the questions in comparison to thirty-seven percent
(22/60) of those women with at least four years of college. Overall, the participants were
more likely to believe that NIPT could test for structural abnormalities (cleft lip, spina bifida
and structure of heart) versus non-structural abnormalities (intellectual disability, autism and
diabetes) (p< 0.0005) and women with less than a four-year degree were even more likely
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than those with higher education to believe that that NIPT could test for both structural
abnormalities (p= 0.024) and non-structural abnormalities (p= 0.010), (Figure 2).
Figure 2: Patient Perception of Conditions Tested by NIPT (n=93)
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%

yes
no
unsure

Worry Levels Before and After Negative NIPT
Participants were asked to rank their worry level about having a child with Down
syndrome, trisomy 13/18 and sex chromosome abnormality pre-testing via NIPT on a scale
of one to five with one being unconcerned and five being very concerned. Similarly, women
were asked what their level of concern was to have a baby with any genetic condition after a
negative NIPT result. There was a significant decline when comparing the general level of
worry before NIPT to each of the worry levels for Down syndrome (p<0.0001), trisomy13/18
(p<0.0001), sex chromosome aneuploidy (p<0.0001) and any other genetic condition after a
negative NIPT result (p<0.0001). Despite the fact that NIPT cannot reduce risk for all genetic
conditions, the majority of participants (n=67, 70%) reported a decrease in worry to have a
baby with any genetic disorder (Table 4).
Table 4: Worry Levels Before and After Negative NIPT (%), n=94

	
   8	
  

Discussion
This study aimed to assess patient perception of the residual risk for Down syndrome,
aneuploidy other than Down syndrome, birth defects, and other genetic conditions, after a
negative non-invasive prenatal test. To our knowledge this is the first study to examine
patient understanding of the limitations of NIPT. Our data demonstrate that despite the
relatively recent implementation of NIPT into obstetric practice, the majority of women who
receive genetic counseling by genetic counselors are aware of its limitations. Overall, most
participants were able to recognize that NIPT is a screening test and that it significantly
reduces risk for those conditions it tests for, but does not eliminate the risk entirely. Of note
for practitioners, patient comprehension of NIPT's screening ability increased significantly
with education level. Therefore, practitioners may need to spend additional time discussing
the implications of a screening test with patients who have less formal education.
Similarly, many women correctly recognized that NIPT does not test for nonstructural abnormalities such as autism, intellectual disability and diabetes or structural
abnormalities such as heart defects, cleft lip and spina bifida. Interestingly, participants were
more likely to incorrectly respond that NIPT could evaluate for structural abnormalities
compared to the non-structural abnormalities. It is unclear why patient comprehension
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differed between these groups. Heart defects and cleft lip are often associated with
aneuploidy, therefore women may have falsely assumed that a negative NIPT reduced the
risk for non-aneuploidy associated heart defects and clefting. In addition, many women at
our participating centers had an ultrasound following their genetic counseling appointment.
Thus, they may have confused reassurance for structural conditions from the ultrasound with
reassurance from NIPT. Furthermore, blood may be drawn to assess alpha fetal protein
(AFP) levels and spina bifida risk at the same time as blood is drawn for NIPT, thus women
may have falsely believed these tests are one in the same. Additional studies may wish to
delve into the underlying reasons behind this misunderstanding.
This study also demonstrated that negative NIPT results significantly decreased worry
levels of patients regarding having a baby with Down syndrome (p <0.00001), trisomy 13/18
(p <0.00001), and sex chromosome aneuploidy (p <0.00001). This asserts the clinical utility
of non-invasive prenatal testing to provide appropriate reassurance for women who
experience anxiety regarding their risk to have a baby with aneuploidy. However, this study
also showed that women who undergo non-invasive prenatal testing are also more likely to
experience a false decrease in worry levels for conditions not screened by NIPT, suggesting
that negative NIPT results may provide patients with false reassurance in addition to
appropriate reassurance for aneuploidy. It is unclear whether or not this is due to lack of
understanding related to NIPT or general unfamiliarity with other genetic conditions.
Although the majority of women are likely to understand the limitations of noninvasive prenatal testing after genetic counseling, it is clear that education level plays a role
in comprehension. Women who had less than a four-year college education were more likely
to believe that their non-invasive prenatal testing could eliminate their risk to have a child
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with aneuploidy. Similarly, women with more education were more likely to understand what
conditions were included in NIPT. These data are consistent with previous studies examining
the role of education on patient literacy and perception of prenatal screening tests. A study by
Wong et al. in 2012 demonstrated that women with less formal education were more likely to
perceive second trimester ultrasound as more sensitive and diagnostic in comparison to those
women with a higher level of education. Moreover, past studies regarding patient
understanding of prenatal maternal serum screening demonstrated that low health literacy
and comprehension of the limitations are associated with less years of formal education
(Goel, 1996; Cho, 2007). Women with low health literacy may also have difficulty with
numeracy, confounding their interpretation of the sensitivity, specificity and predictive
values of prenatal screening methods. In 2004 Gates et al. examined the role of numeracy on
patient understanding and concluded that women with lower levels of literacy and numeracy
have the most difficulty in accurately interpreting information about risk. The effect of
education and health literacy on patient understanding of prenatal screening is an important
consideration, as approximately 40% of women 25 years and older in the United States do
not have any formal education beyond high school (US Census Data 2014).
An additional issue that may confuse patients is the manner in which the 99%
detection rate for NIPT is often highlighted by the media and laboratory testing materials
rather than focusing on the individual patient’s PPV and NPV. Without sufficient
background knowledge, women may get the impression that the PPV and detection rates are
both 99%. A study by Mercer et al. in 2014 examined the impact of the availability and use
of the Internet for gathering information about non-invasive prenatal testing. Their study
showed a lack of comprehensiveness and quality of information regarding non-invasive
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prenatal testing obtained through Internet sources. Moreover, many of the websites either
failed to mention or downplayed information about the limitations and disadvantages of
NIPT while simultaneously promoting the accuracy of the test without mentioning the
importance of negative and positive predictive value calculations. It is no wonder that
women who research NIPT on the Internet may not appreciate the residual risk for
aneuploidy, especially women without advanced formal education.
Conclusions and future directions
This study demonstrates that NIPT invokes similar issues as previous prenatal
screening modalities and that providers should be cognizant of the tendency for women with
less formal education to overinflate the power of screening to decrease or eliminate their risk
for a baby with a genetic condition. The incorporation of non-invasive prenatal testing into
obstetric practice has proved both exciting and overwhelming. Although it is clear that this
new screening option can provide tremendous benefits to women worried about having a
baby with a common aneuploidy, proper pretest genetic counseling is essential to ensure that
patients are informed of the limitations and potential results from NIPT. There appear to be
numerous barriers to complete patient comprehension of non-invasive prenatal testing,
including the low numeracy and health literacy of many members of the general population
and the potentially misleading portrayal of the limitations of NIPT on the Internet. Genetic
counselors and obstetricians must prioritize communicating information regarding NIPT
accurately and clearly, so that women considering it as a screening option may be adequately
informed. When possible, attention should be paid to a patient’s education level and
information should be tailored accordingly. The development of patient friendly decision aids
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that clearly state the limitations of screening and what a negative test means may assist in
residual risk communication, informed consent, and decision making (Vlemmix et al. 2013).
As this was a pilot study with a limited number of participants, more research is
needed to examine patient perception of the limitations of non-invasive prenatal testing and
how this may vary based on patient demographic and geographic factors. Additionally, future
studies may wish to examine whether the implementation of targeted educational materials
and decision aids augment patient understanding of NIPT, especially as the testing platforms
are expanded to cover more chromosomal abnormalities. Furthermore, research should be
done to assess patient perception of positive NIPT results and whether or not women who
screen positive accurately understand the implications and limitations of the results.
Limitations
This study was limited by the small sample size. The majority of women were
referred either due to advanced maternal age or positive serum screen. Therefore, we cannot
confidently extrapolate to the low risk population. In addition, 64% of participants had at
least a 4-year college degree. Given the association of education level with understanding, a
larger sample size might have allowed for parsing out sub-groups from women who had less
than a four year degree into those with some college, those with a high school diploma, and
those without a high school diploma to further stratify the finding. Additionally, the survey
used was carefully developed to evaluate the aims of this study; however, this assessment
tool has not been validated in other studies. Finally, this research was limited to the greater
Houston, Texas area, thus these results may not be generalizable to other geographical
regions.
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Appendix A
Patient consent form
INFORMED CONSENT FORM TO TAKE PART IN RESEARCH
Title: Patient perception of residual risk post negative NIPT results
Letter of Information
HSC-MS-15-0444
Primary Investigator: Claire Singletary
You are invited to take part in a research study called, “Patient perception of residual risk post
negative NIPT results”, conducted by Claire Singletary of the University of Texas Health Science
Center at Houston. For this research project, she will be called the Principal Investigator or PI.
The purpose of this study is to evaluate patient perception of their negative NIPT results. If you
decide to take part in the study, the total time commitment is 15 minutes. You are invited to take part
in this study because you have elected to proceed with non-invasive prenatal testing (NIPT). Women
who choose to participate will be contacted after they receive their NIPT results. You can refuse to
answer any questions asked or written on any forms. Participation in this study is voluntary. A
decision not to take part in this study will not change the services you receive through the University
of Texas Health Science Center at Houston.
If you agree to take part in this survey, you will agree to a 15 minute survey.
You may not receive any benefit from taking part in this study. The information you provide will
help to determine patient understanding of non-invasive prenatal testing. There are no known risks to
take part in this study. The only possible risk may be breach of confidentiality. This information
collected in the survey responses will not contain identifying information and will be kept on a secure
server. You have the alternative to choose to not take part in this study and can withdraw at any time.
There is no cost and you will not be paid to take part in this study. However, upon completion of the
survey you can choose to be entered in a drawing to win a $50 Target gift card. You will not be
personally identified in any reports or publications that may result from this study. Any personal
information about you that is gathered during this study will remain confidential to every extent of the
law.
If you have any questions about this project please contact study coordinator Theresa Wittman or PI
Claire Singletary at 713–500-5599.
If you would like to be contacted to participate after you receive your NIPT results, please provide the
following information:
Name: __________________________________
Email: ___________________________________
Phone Number:___________________
Signature: _______________________________
Date: ___________________________
If you agree to take part in the study your agreement is completion of the survey.
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This research project has been reviewed by the Committee for the Protection of Human Subjects
(CPHS) of the University of Texas Health Science Center at Houston (HSC-MS-15-0444) For any
questions about research subjects rights call CPHS at (713) 500-7943.

For genetic counselor use only:
Date: ______________
Indication:
AMA
Positive FTS Screen Positive Quad Screen Ultrasound
Abnormality Positive Family History
Other __________________________________
Age: ___________
G: _____________P: _________
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Appendix B
Prenatal patient questionnaire
You were seen for genetic counseling during your current pregnancy and offered to
participate in a survey about having a blood test called non-invasive prenatal testing, or
NIPT. Thank you for agreeing to be contacted to discuss your feelings about NIPT.
This survey should take approximately 10 minutes to complete. Whether or not you choose
to participate will not impact your care in any way. Your participation is greatly appreciated.
Please choose the best answer for each question:
1. How many years of education you have completed?
a. Never attended high school
b. Some high school
c. High school/GED
d. Some college or 2 year/associates degree
e. 4-year degree (BA, BS)
f. Graduate or Professional degree (MS, MBA, PhD, MD, JD)
g. Do not wish to answer
2. What is your marital status?
a. Married/living with partner
b. Unmarried, living with other adults
c. Unmarried, living without other adults
d. Do not wish to answer
3. With which race/ethnicity do you most identify?
a. White, non-Hispanic
b. Hispanic
c. African-American
d. Asian/Pacific Islander
e. Native American
f. Other: __________________________________
g. Do not wish to answer
4. On a scale of 1 to 5, with 1 being unconcerned and 5 being very concerned, please rate
what your level of concern was for your baby to have any health problem before you had
non-invasive prenatal testing (NIPT)
1 2
3 4 5
5. On a scale of 1 to 5, with 1 being unconcerned and 5 being very concerned, please rate
what your level of concern was to have a baby with a health problem, before you had noninvasive prenatal testing (NIPT)
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1

2

3

4

5

6. You had a negative NIPT test. What do you feel that your chances are to have a baby with
Down syndrome after receiving this result? After receiving a negative NIPT result I feel my
chances are…
a. Not lower than before
b. Somewhat lower than before
c. Much lower than before
d. There is no longer a chance that my baby will have Down syndrome
7. On a scale of 1 to 5, with 1 being unconcerned and 5 being very concerned, please select
what your present level of concern is to have a baby with Down syndrome after a negative
NIPT result
1 2
3 4 5
8. What are your chances to have a baby with trisomy 18 or trisomy 13 after receiving a
negative NIPT result? After receiving a negative NIPT result I feel my chances are…
a. Not lower than before
b. Somewhat lower than before
c. Much lower than before
d. There is no longer a chance that my baby will have trisomy 13 or trisomy 18
9. On a scale of 1 to 5, with 1 being unconcerned and 5 being very concerned, please select
what your present level of concern is to have a baby with a baby with trisomy 18 or trisomy
13 after receiving a negative NIPT result
1 2
3 4 5
10. What are your chances to have a baby with a sex chromosome condition such as Turner
syndrome or Klinefleter syndrome after receiving a normal NIPT result?
After receiving a negative NIPT result I feel my chances are…
a. Not lower than before
b. Somewhat lower than before
c. Much lower than before
d. There is no longer a chance that my baby will have a sex chromosome condition
11. On a scale of 1 to 5, with 1 being unconcerned and 5 being very concerned, please select
what your present level of concern is to have a baby with a sex chromosome condition after a
negative NIPT result.
1 2
3 4 5
12. What are your chances to have a baby with a genetic condition other than Down
syndrome, trisomy 18, trisomy 13 or a sex chromosome conditions after receiving a normal
NIPT result? After receiving a negative NIPT result I feel my chances are…
a. Not lower than before
b. Somewhat lower than before
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c. Much lower than before
d. There is no longer a chance that my baby will have any genetic condition other than
other than Down syndrome, trisomy 18, trisomy 13 or a sex chromosome condition
13. Please select your level of worry about having a baby with a genetic condition other than
Down syndrome, trisomy 18, trisomy 13 or sex chromosome condition
1 2
3 4 5
14. Please select whether NIPT is able to specifically test for any of the following:
a.
b.
c.
d.
e.
f.
g.

Spina bifida
Cleft lip
Gender
Structure of heart
Intellectual disability
Autism
Diabetes

Yes
Yes
Yes
Yes
Yes
Yes
Yes

No
No
No
No
No
No
No

Don’t know
Don’t know
Don’t know
Don’t know
Don’t know
Don’t know
Don’t know

15. Have you had your anatomy ultrasound (typically performed around 20 weeks of
pregnancy)?
Yes No
If yes, were any abnormalities found on your ultrasound?
If yes, please describe: ______________________
16. Did you have an amniocentesis procedure (needle test) or chorionic villus sampling
(CVS) after receiving your negative NIPT results?
Yes
No
17. Are you planning to have an amniocentesis procedure (needle test) or chorionic villus
sampling (CVS)? after receiving your negative NIPT results?
Yes No
18. If yes, why did you or why will you have an amniocentesis or CVS? (check all that
apply)
• Concerns from my NIPT
• Concerns on an ultrasound
• For piece of mind
• For greater accuracy
• To test for other conditions
• Other:
19. If you did not or will not have an amniocentesis (needle test) or chorionic villus sampling
(CVS), why not? (check all that apply)
• NIPT results were reassuring enough
• My doctor/genetic counselor said I did not need it
• The risk of miscarriage
• I am not worried about other conditions NIPT did not test for
• I am not worried about Down syndrome, trisomy 18, trisomy 13 or sex chromosome
conditions
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•
•
•

I do not like needles
I will continue the pregnancy regardless of a genetic condition
Other: ______________________

20. If your NIPT testing had come back abnormal, were you planning to have an
amniocentesis or CVS?
Yes
No
Unsure
Why or Why Not?
21. How has having a negative NIPT test impacted your worry level about the pregnancy?
(please check)
a. I worry much less
b. I worry a little less
c. I worry about the same
d. I worry a little more
e. I worry a great deal more
22. Rank from most important (1) to least important (6) the reasons behind your decision to
pursue NIPT?
______To determine my baby’s gender
______To determine my baby’s chance of having Down syndrome
______To determine my baby’s chance of having another chromosome condition, such as
trisomy 18, trisomy 13, or a sex chromosome disorder
______ To avoid having amniocentesis or CVS
______ To make my doctor happy
______ To relieve anxiety
23. Please describe below any other reason not listed above that was important in your
decision- to pursue NIPT
24. Please describe below any other comments or concerns you have regarding your noninvasive prenatal testing?
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